Navigation path

Stakeholder event on Biosimilar medicinal products 30-10-2019 FINAL AGENDA
A Snapshot of the Biosimilar Market Dynamics_IQVIA Report 2019
Market Dynamics from a DG COMP Perspective
Tools to Optimize Biosimilars Benefits from a Societal Perspective_HU Semmelweis University
Biosimilars in Slovakia_A Slovakian Union Health Insurance Fund Perspective
Update on Biosimilars in Germany_A German Physicians Association (KVWL) Perspective
Promoting the Use of Biosimilars in France_A FR Ministry of Solidarity & Health Perspective
How to Improve Early Access to Biosimilars_A Pharmacist's Perspective
Sustainable Procurement of Medicines_A Perspective from DG GROW
Biosimilars in the EU_A paradigm in Regulatory Science_A European Medicines Agency Perspective
Ways to Foster Biosimilars Access to Patients_A Clinician Perspective
How to Improve Early Access to Biosimilars_A Patients Organisation Perspective
How to Improve Early Access to Biosimilars_A European Specialist Nurses Organisation Perspective
Danish Experience with Biosimilars_A Danish Medicines Agency Perspective
Biosimilars in Hungary_A Hungarian Institute of Health Insurance Fund Perspective
List of organisations which attended the conference
2019 IQVIA Report - The Impact of Biosimilar Competition in Europe
Commission reply to a Petition "For a Compensation Fund for PIP Breast Implants and CE" from the website
Meeting Summary - Multi-stakeholder Workshop on Biosimilar Medicinal Products
IQVIA Report 2018: The impact of biosimilar competition in Europe
Final Agenda Stakeholder Event on Biosimilar Medicinal Products - 14/09/2018
Biosimilars introduction in Denmark
Biosimilars use in Oncology Overview by the EMA on biosimilars approved so far
Aim of the European Society of Oncology Pharmacy ESOP
Biosimilars use in oncology_The role of Cancer Nurses
Results per page: 5 10 15 20 25 | Page 1 out of 3

Additional tools